Abstract
SARS-CoV-2 RNA can be detected in the excreta of individuals with COVID-19 and has demonstrated a positive correlation with various clinical parameters. Consequently, wastewater-based epidemiology (WBE) approaches have been implemented globally as a public health surveillance tool to monitor the community-level prevalence of infections. Over 270 higher education campuses monitor wastewater for SARS-CoV-2, with most gathering either composite samples via automatic samplers (autosamplers) or grab samples. However, autosamplers are expensive and challenging to manage with seasonal variability, while grab samples are particularly susceptible to temporal variation when sampling sewage directly from complex matrices outside residential buildings. Prior studies have demonstrated encouraging results utilizing passive sampling swabs. Such methods can offer affordable, practical, and scalable alternatives to traditional methods while maintaining a reproducible SARS-CoV-2 signal. In this regard, we deployed tampons as passive samplers outside of a COVID-19 isolation unit (a segregated residence hall) at a university campus from February 1, 2021 – May 21, 2021. Samples were collected several times weekly and remained within the sewer for a minimum of 24 hours (n = 64). SARS-CoV-2 RNA was quantified using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) targeting the viral N1 and N2 gene fragments. We quantified the mean viral load captured per individual and the association between the daily viral load and total persons, adjusting for covariates using multivariable models to provide a baseline estimate of viral shedding. Samples were processed through two distinct laboratory pipelines on campus, yielding highly correlated N2 concentrations. Data obtained here highlight the success of passive sampling utilizing tampons to capture SARS-CoV-2 in wastewater coming from a COVID-19 isolation residence, indicating that this method can help inform public health responses in a range of settings.
Highlights
Daily SARS-CoV-2 RNA loads in building-level wastewater were positively associated with the total number of COVID-19 positive individuals in the residence
The variation in individual fecal shedding rates of SARS-CoV-2 extended four orders of magnitude
Wastewater sample replicates were highly correlated using distinct processing pipelines in two independent laboratories
While the isolation residence was occupied, SARS-CoV-2 RNA was detected in all passive samples
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported with special funds from the Office of Research & Engagement at the University of Massachusetts and by Mike Malone, Vice Chancellor for Research & Engagement. As well, this research was supported with funds from The Environmental Health Science Summer Research Fellowship supported by the National Institute of Environmental Health Sciences (#R25ES031498). The Institute for Applied Life Sciences Clinical Testing Center was integral in performing the sample analysis reported in this work as part of their clinical testing operations, notably acknowledging Ashley Eaton and Peter Reinhart. This research was also funded by the Massachusetts Department of Transportation Highway Division (MassDOT) under Interagency Service Agreement No. 106059. The views, opinions, and findings contained in this paper are those of its Authors, and do not necessarily reflect the official view or policies of the MassDOT. This paper does not constitute a standard, specification, or regulation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Human Research Protection Office (HRPO) at the University of Massachusetts Amherst, which is the administrative hub for the University's Human Research Protection Program (HRPP) and Institutional Review Board (IRB) waived ethical approval for this work (approval #21-140).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
